Expression, localization, and functional coupling of the somatostatin receptor subtype 2 in a mouse model of oxygen-induced retinopathy

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 4, 2010, Pages 1848-1856

  Monte, Massimo Dal ^a   Ristori, Chiara ^a   Videau, Catherine ^b   Loudes, Catherine ^b   Martini, Davide ^a   Casini, Giovanni ^c   Epelbaum, Jacques ^b   Bagnoli, Paola ^a  

^a UNIVERSITY OF PISA   (Italy)

^b INSERM   (France)

^c UNIVERSITY OF TUSCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYANAMIDE; OCTREOTIDE; OCTREOTIDE[3 TYROSINE]; OXYGEN; SOMATOSTATIN RECEPTOR 2; STAT3 PROTEIN; CYN 154806; OLIGOPEPTIDE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; SSTR2 PROTEIN, MOUSE; STAT3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; FEMALE; HYPOXIA; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RADIOIMMUNOASSAY; RETINA CAPILLARY; RETINOPATHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; ANOXIA; AUTORADIOGRAPHY; C57BL MOUSE; DISEASE MODEL; DRUG ANTAGONISM; DRUG POTENTIATION; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; METABOLISM; NEWBORN; PATHOLOGY; RETINA BLOOD VESSEL; RETROLENTAL FIBROPLASIA;

ANIMALS; ANIMALS, NEWBORN; ANOXIA; AUTORADIOGRAPHY; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; INFANT, NEWBORN; MALE; MICE; MICE, INBRED C57BL; OCTREOTIDE; OLIGOPEPTIDES; OXYGEN; RADIOIMMUNOASSAY; RECEPTORS, SOMATOSTATIN; RETINAL VESSELS; RETINOPATHY OF PREMATURITY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SOMATOSTATIN; STAT3 TRANSCRIPTION FACTOR;

EID: 77951243416     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4472     Document Type: Article

References (58)

1. Hernandez C, Simò R. Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice. Expert Opin Investig Drugs. 2007;16:1209-1226.
2. Dal Monte M, Cammalleri M, Martini D, Casini G, Bagnoli P. Antiangiogenic role of somatostatin receptor 2 in a model of hypoxia-induced neovascularization in the retina: results from transgenic mice. Invest Ophthalmol Vis Sci. 2007;48:3480-3489.
3. Casini G, Dal Monte M, Petrucci C, et al. Altered morphology of rod bipolar cell axonal terminals in the retinas of mice carrying genetic deletion of somatostatin subtype receptor 1 or 2. Eur J Neurosci. 2004;19:43-54.
4. Dal Monte M, Petrucci C, Vasilaki A, et al. Genetic deletion of somatostatin receptor 1 alters somatostatinergic transmission in the mouse retina. Neuropharmacology. 2003;45:1080-1092.
5. Dal Monte M, Ristori C, Cammalleri M, Bagnoli P. Somatostatin analogs affect retinal angiogenesis in a mouse model of oxygeninduced retinopathy: involvement of the somatostatin receptor subtype 2. Invest Ophthalmol Vis Sci. 2009;50:3596-3606.
6. Cristiani R, Petrucci C, Dal Monte M, Bagnoli P. Somatostatin (SRIF) and SRIF receptors in the mouse retina. Brain Res. 2002; 936:1-14.
7. Bagnoli P, Dal Monte M, Casini G. Expression of neuropeptides and their receptors in the developing retina of mammals. Histol Histopathol. 2003;18:1219-1242.
8. Klisovic DD, O'Dorisio MS, Katz SE, et al. Somatostatin receptor gene expression in human ocular tissues: RT-PCR and immunohistochemical study. Invest Ophthalmol Vis Sci. 2001;42:2193-2201.
9. Lambooij AC, Kuijpers RW, van Lichtenauer-Kaligis EG, et al. Somatostatin receptor 2A expression in choroidal neovascularization secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2000;41:2329-2335.
10. Adams RL, Adams IP, Lindow SW, Zhong W, Atkin SL. Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br J Cancer. 2005;92:1493-1498.
11. Bartoli M, Al-Shabrawey M, Labazi M, et al. HMG-CoA reductase inhibitors (statin) prevents retinal neovascularization in a model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2009;50: 4934-4940.
12. Mechoulam H, Pierce EA. Expression and activation of STAT3 in ischemia-induced retinopathy. Invest Ophthalmol Vis Sci. 2005; 46:4409-4416.
13. Zhang C, Li H, Liu MG, et al. STAT3 activation protects retinal ganglion cell layer neurons in response to stress. Exp Eye Res. 2008;86:991-997.
14. Dace DS, Khan AA, Kelly J, Apte RS. Interleukin-10 promotes pathological angiogenesis by regulating macrophage response to hypoxia during development. PLoS One. 2008;3:e3381.
15. Platt DH, Bartoli M, El-Remessy AB, et al. Peroxynitrite increases VEGF expression in vascular endothelial cells via STAT3. Free Radic Biol Med. 2005;39:1353-1361.
16. Bartoli M, Platt D, Lemtalsi T, et al. VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J. 2003;17:1562-1564.
17. Bartoli M, Gu X, Tsai NT, et al. Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells. J Biol Chem. 2000;275:33189-33192.
18. Smith LEH, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35: 101-111.
19. Olias G, Viollet C, Kusserow H, Epelbaum J, Meyerhof W. Regulation and function of somatostatin receptors. J Neurochem. 2004; 89:1057-1091.
20. 2 receptor antagonist CYN 154806. Naunyn Schmiedebergs Arch Pharmacol. 2003; 367:1-9.
21. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov. 2003;2:999-1017.
22. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 2000;132:365-386.
23. Pattyn F, Speleman F, De Paepe A, Vandesompele J. RTPrimerDB: the real-time PCR primer and probe database. Nucleic Acids Res. 2003;31:122-123.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-408.
25. Grouselle D, Winsky-Sommerer R, David JP, Delacourte A, Dournaud P, Epelbaum J. Loss of somatostatin-like immunoreactivity in the frontal cortex of Alzheimer patients carrying the apolipoprotein epsilon 4 allele. Neurosci Lett. 1998;255:21-24.
26. Moyse E, Beaudet A, Bertherat J, Epelbaum J. Light microscopic radioautographic localization of somatostatin binding sites in the brainstem of the rat. J Chem Neuroanat. 1992;5:75-84.
27. DeNiro M, Alsmadi O, Al-Mohanna F. Modulating the hypoxiainducible factor signaling pathway as a therapeutic modality to regulate retinal angiogenesis. Exp Eye Res. 2009;89:700-717.
28. Catalani E, Cervia D, Martini D, et al. Changes in neuronal response to ischemia in retinas with genetic alterations of somatostatin receptor expression. Eur J Neurosci. 2007;25:1447-1459.
29. Mastrodimou N, Vasilaki A, Papadioti A, Low MJ, Hoyer D, Thermos K. Somatostatin receptors in wildtype and somatostatin deficient mice and their involvement in nitric oxide physiology in the retina. Neuropeptides. 2006;40:365-373.
30. Zhang HR. Scanning electron-microscopic study of corrosion casts on retinal and choroidal angioarchitecture in man and animals. Prog Ret Eye Res. 1994;13:243-270.
31. Cervia D, Casini G, Bagnoli P. Physiology and pathology of somatostatin in the mammalian retina: a current view. Mol Cell Endocrinol. 2008;286:112-122.
32. Carrasco E, Hernández C, Miralles A, Huguet P, Farrés J, Simó R. Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal neurodegeneration. Diabetes Care. 2007;30:2902-2908.
33. Hernandez C, Carrasco E, Casamitjana R, Deulofeu R, García-Arumí J, Simó R. Somatostatin molecular variants in the vitreous fluid: a comparative study between diabetic patients with proliferative diabetic retinopathy and nondiabetic control subjects. Diabetes Care. 2005;28:1941-1947.
34. Simó R, Lecube A, Sararols L, et al. Deficit of somatostatin-like immunoreactivity in the vitreous fluid of diabetic patients: possible role in the development of proliferative diabetic retinopathy. Diabetes Care. 2002;25:2282-2286.
35. Cervia D, Martini D, Ristori C, et al. Modulation of the neuronal response to ischaemia by somatostatin analogues in wild-type and knock-out mouse retinas. J Neurochem. 2008;106:2224-2235.
36. 2 analogs on AMPA-induced neurotoxicity in rat retina. Invest Ophthalmol Vis Sci. 2008;49:3080-3089.
37. Feoktistov I, Ryzhov S, Zhong H, et al. Hypoxia modulates adenosine receptors in human endothelial and smooth muscle cells toward an A2B angiogenic phenotype. Hypertension. 2004;44: 649-654.
38. Zhu M, Li MW, Tian XS, Ou XM, Zhu CQ, Guo JC. Neuroprotective role of delta-opioid receptors against mitochondrial respiratory chain injury. Brain Res. 2009;1252:183-191.
39. Huang Y, Zhao JJ, Lv YY, Ding PS, Liu RY. Hypoxia down-regulates glucocorticoid receptor alpha and attenuates the anti-inflammatory actions of dexamethasone in human alveolar epithelial A549 cells. Life Sci. 2009;85:107-112.
40. Siehler S, Seuwen K, Hoyer D. Characterisation of human recombinant somatostatin receptors, 1: radioligand binding studies. Naunyn Schmiedebergs Arch Pharmacol. 1999;360:488-499.
41. Thermos K, Bagnoli P, Epelbaum J, Hoyer D. The somatostatin sst1 receptor: an autoreceptor for somatostatin in brain and retina? Pharmacol Ther. 2006;110:455-464.
42. Cristiani R, Fontanesi G, Casini G, Petrucci C, Viollet C, Bagnoli P. Expression of somatostatin subtype 1 receptor in the rabbit retina. Invest Ophthalmol Vis Sci. 2000;41:3191-3199.
43. Kaur C, Sivakumar V, Foulds WS, Luu CD, Ling EA. Cellular and vascular changes in the retina of neonatal rats following an acute exposure to hypoxia. Invest Ophthalmol Vis Sci. 2009;50:5364-5374.
44. Watson JC, Balster DA, Gebhardt BM, et al. Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br J Cancer. 2001;85:266-272.
45. van Hagen PM, Baarsma GS, Mooy CM, et al. Somatostatin and somatostatin receptors in retinal diseases. Eur J Endocrinol. 2000; 143(suppl 1):S43-S51.
46. Mejias M, Garcia-Pras E, Tiani C, Bosch J, Fernandez M. The somatostatin analogue octreotide inhibits angiogenesis in the ear-liest, but not in advanced, stages of portal hypertension in rats. J Cell Mol Med. 2008;12:1690-1699.
47. Qu Y, Zhang S, Xu X, et al. Octreotide inhibits choroidal neovascularization in rats. Ophthalmic Res. 2009;42:36-42.
48. Guma M, Rius J, Duong-Polk KX, Haddad GG, Lindsey JD, Karin M. Genetic and pharmacological inhibition of JNK ameliorates hypoxia-induced retinopathy through interference with VEGF expression. Proc Natl Acad Sci USA. 2009;106:8760-8765.
49. Phng LK, Potente M, Leslie JD, et al. Nrarp coordinates endothelial Notch and Wnt signaling to control vessel density in angiogenesis. Dev Cell. 2009;16:70-82.
50. Noman MZ, Buart S, Van Pelt J, et al. The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol. 2009;182:3510-3521.
51. Gray MJ, Zhang J, Ellis LM, et al. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene. 2005;24:3110-3120.
52. Niu G, Wright KL, Huang M, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002;21:2000-2008.
53. Schaefer LK, Ren Z, Fuller GN, Schaefer TS. Constitutive activation of Stat3alpha in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). Oncogene. 2002;21:2058-2065.
54. Ozawa Y, Nakao K, Kurihara T, et al. Roles of STAT3/SOCS3 pathway in regulating the visual function and ubiquitin-proteasome-dependent degradation of rhodopsin during retinal inflammation. J Biol Chem. 2008;283:24561-24570.
55. Ueki Y, Wang J, Chollangi S, Ash JD. STAT3 activation in photoreceptors by leukemia inhibitory factor is associated with protection from light damage. J Neurochem. 2008;105:784-796.
56. Al-Shabrawey M, Bartoli M, El-Remessy AB, et al. Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy. Invest Ophthalmol Vis Sci. 2008;49:3231-3238.
57. Oomen SP, Ward AC, Hofland LJ, Lamberts SW, Löwenberg B, Touw IP. Somatostatin modulates G-CSF-induced but not interleukin-3-induced proliferative responses in myeloid 32D cells via activation of somatostatin receptor subtype 2. Hematol J. 2001;2: 322-329.
58. Florio T. Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatases. Mol Cell Endocrinol. 2008;286:40-48.